Introduction
As the first step of gene expression, transcription requires accurate reading of the genetic code from the DNA template strand and faithful synthesis of a complementary messenger RNA strand by the action of an essential enzyme, RNA polymerase II (Pol II).
The fidelity of this process depends not only on the specific patterns of hydrogen bonds between complementary nucleotide base pairs, but also relies on the specific recognition of the template DNA strand and correct selection of NTP substrates by Pol II. DNAtargeted chemotherapeutic drugs alter the chemical and structural properties of the duplex and subsequently modulate transcription and other DNA-dependent cellular processes that lead to the beneficial clinical outcome. Knowledge of the functional interplay between drug-induced DNA modifications and transcription will enhance our understanding of the mechanism of action of these drugs and guide rational improvements in drug design.
The three FDA-approved platinum antitumor drugs, cisplatin (cis-diamminedichloroplatinum(II)), carboplatin (cis-diammine(1,1'-cyclobutanedicarboxylato)platinum(II)), and oxaliplatin ((trans-R,R-diaminocyclohexane)oxalatoplatinum(II)) ( Figure 1a ), [1] [2] [3] [4] [5] [6] form bifunctional platinum-DNA cross-links. The major platinum-DNA adducts are strong roadblocks for Pol II transcription and result in cell death. [7] [8] [9] However, recurrence of the disease often occurs as a result of acquired or intrinsic resistance to these platinum-based drugs, owing to repair of the adducts before they can destroy the cancer cell.
New platinum-based chemotherapeutics with novel mechanisms of action are needed to overcome these limitations. 1, [10] [11] [12] [13] [14] [15] [16] ! ! 5! phenanthridinechloroplatinum(II)) ( Figure 1a ), were identified that display a unique spectrum of activity against panels of cancer cell lines. This behavior differentiates them as having a structure-activity relationship distinct from that of cisplatin and its analogs, which form DNA cross-links. [12] [13] [14] [15] In contrast to cisplatin, these compounds exclusively form monofunctional adducts, mainly at the N 7 positions of dG and dA deoxynucleotides on the DNA template ( Figure 1b ). 15 Previously, we reported the structure of Pol II stalled at a pyriplatin-DNA monofunctional adduct. 14 This structure revealed that the adduct introduces a strong steric barrier for Pol II translocation by interacting with the Pol II bridge helix and blocking transition to the next base on the template strand. The mechanism of transcription inhibition by pyriplatin thus differs significantly from that of cisplatin. 14 Transcription inhibition profiles for pyriplatin-DNA adducts were further characterized in a variety of live mammalian cell lines. 16 To improve the potency of monofunctional Pt(II) complexes, various Nheterocyclic ligands (Am) were substituted for pyridine, with guidance from the X-ray structure of Pol II stalled at the pyriplatin-DNA adduct. 14 Among these compounds, phenanthriplatin had the greatest activity, significantly better than that of the three FDAapproved drugs. 15 With the use of globally platinated Gaussia luciferase vectors, we determined that transcription is inhibited by phenanthriplatin treatment in live mammalian cells. 15 To gain a deeper mechanistic insight into the action of phenanthriplatin, it is important to determine how specific DNA adducts made by the complex will affect transcription in a defined system using purified RNA Pol II, the enzyme responsible for synthesizing most mRNAs, snRNA, and microRNAs. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The transcriptional fidelity of Pol II is controlled by three checkpoint steps: (1) specific nucleotide selection and incorporation; (2) preferential RNA transcript extension from a matched end; and (3) proofreading by cleavage of the RNA transcript at 3'-end ( Figure 1c ). 32 In the first checkpoint step, the nucleotide substrate diffuses into the active site of RNA Pol II through its secondary channel. If the substrate is matched with the template base, the trigger loop folds into an active closed conformation. The nucleotide addition reaction is greatly facilitated by this closure of the active site. 20 On the other hand, when a mismatched nucleotide is located at the E site, the trigger loop remains in an inactive, open state. 19, 20 As a consequence, addition of the mismatched nucleotide is very slow and inefficient. In the second checkpoint step, Pol II can elongate much more efficiently from a matched than a mismatched end, providing a strong kinetic discrimination and opening a time window for the next checkpoint step (Pol II proofreading). 32 Finally, Pol II achieves its proofreading activity by backtracking and preferentially cleaving RNA transcripts that have a mismatched rather than a matched end. 26, 32 We recently reported a systematic analysis of the roles that specific hydrogen bonds between base pairs and base stacking play in each of the three fidelity checkpoint steps. 32 In the present investigation we have dissected the functional interplay between a site-specific phenanthriplatin-DNA dG adduct, the most abundant lesion made by the compound on the duplex, and the Pol II transcription machinery as an important step toward elucidating the mechanism of phenanthriplatin. Although formation of this adduct on the DNA template strand does not directly interfere with G:C Watson-Crick base pairing,
it was designed to introduce significant steric hindrance to Pol II on the major groove side of the guanosine base. Here, we present the effect of this adduct on each of the transcriptional fidelity checkpoint steps and report a comprehensive analysis of the functional interplay between the programmed phenanthriplatin-DNA lesion and Pol II transcription.
Experimental Section

Preparation of a DNA Template Containing a Site-Specific Phenanthriplatin dG
Adduct. The DNA template containing the site-specific phenanthriplatin-DNA adduct used in transcription assays is as follows:
where G* refers to the phenanthriplatin DNA adduct ( Figure 1 ). The material was prepared and purified by HPLC essentially as described. 15 Detailed procedures for synthesis and characterization are given in the Supporting Information.
Preparation of Pol II Elongation Complex. Saccharomyces cerevisiae yeast Pol II was purified as described. 20, 26, 31, 32 Pol II elongation complexes containing the desired DNA/RNA scaffolds were prepared as described. 20, 26, 32 Briefly, an aliquot of 5'- 32 Scaffold A:
In Vitro Pol II Transcription Elongation Assays. The assay was performed as described. 32 Briefly, aliquots of preformed Pol II elongation complex with scaffold A or B Single-Turnover Nucleotide Incorporation Assays. The assay was carried out as previously described. 32 Briefly, nucleotide incorporation was monitored by pre-incubating 100 nM 10! ucts were analyzed by denaturing PAGE as previously described and quantitated with a Molecular Imager PharosFX Plus system (Bio-Rad) and Image Lab software.
Single-Turnover TFIIS-Mediated and Pyrophosphate-Mediated Cleavage Assays.
TFIIS-mediated cleavage reactions were performed by pre-incubating Pol II with various scaffolds as previously described. 32 The Data Analysis of Nucleotide Incorporation Kinetics. Data analysis was performed as described. 32 Briefly, the time dependence of transcription product formation at a single concentration of NTP was fit by non-linear regression analysis to an exponential equation using GraFit 5. The NTP concentration dependence of the observed fast rate was then fit to a hyperbolic equation to obtain values for the maximum rate of NTP incorporation (k pol ) and a dissociation constant (K d,app ). The specificity constant (k cat /K m ) was then obtained from k pol /K d,app . Discrimination was calculated as the ratio of specificity constants governing two different nucleotide incorporation events defined in the text.
Results
To investigate the effect of a phenanthriplatin monofunctional dG adduct on RNA Pol II transcription elongation bypass and fidelity, we assembled active RNA Pol II elon- incorporation efficiency is the greatest and GTP the lowest (Figure 2b ). In addition, we observed a measureable amount of UTP and ATP misincorportion at prolonged incubation times and higher concentrations (Figure 2b ). Because CTP, ATP, and UTP incorporation opposite the platinum adduct are much more efficient than GTP incorporation, we compared the efficiency of installing these three substrates, CTP being correct but ATP and UTP introducing mutations in RNA transcripts. To provide a quantitative measurement of the effect of the phenanthriplatin-DNA adduct on their first checkpoint step, Pol II nucleotide selection and incorporation, we per-
formed pre-steady-state single turnover transcription assays. The kinetic parameters, k pol (catalytic rate constant) and K d,app (apparent dissociation constant), for CTP, ATP and UTP incorporation were determined using the platinated and unplatinated templates.
As can be seen from Table 1 ATP and UTP misincorporation was significantly slower than CTP incorporation for both damaged and undamaged templates ( Table 1 and Figure 3a ). Interestingly, there was no significant difference in k pol for misincorporation of ATP and UTP on the platinated compared to the unplatinated template. (Figures 4b, c , and e, f). We further tested the extension ability of these six transcription complexes with a NTP incubation mixture, and we observed that the presence of the DNA lesion significantly reduces the longer transcription products, especially transcripts longer than 15 nt, which are virtually abolished (Figure 4 ). This result is consistent with the data obtained using scaffold A with a shorter RNA primer. Collectively, discrimination of a matched over a mismatched 3'-RNA terminus decreases significantly as a consequence of phenanthriplatin damage on the DNA template.
GTP incorporation on the C:dG template is favored by 2,000-fold and 5,000-fold over the A:dG and U:dG mismatch, respectively (Figure 6b ). This value decreases significantly with replacement of dG by Pt-dG on the template such that GTP incorporation on the C:Pt-dG scaffold is favored by only ~9-fold and ~14-fold compared with the A:Pt-dG and U:Pt-dG scaffolds, respectively (Figure 6b ). Thus, the presence of Pt-DNA lesion significantly slows down incorporation the next nucleotide and greatly diminishes the strong kinetic discrimination of transcript extension from a matched over a mismatched end.
Effect of a Phenanthriplatin-DNA Lesion on the Third Checkpoint Step: Pol II
Proofreading of RNA Transcripts. Finally, we investigated the effect of a phenanthriplatin-dG lesion on the third checkpoint step, Pol II proofreading, by performing TFIIS-stimulated cleavage assays using scaffold B in the absence of NTP. The results are presented in Figure 7 and summarized in Table 4 . It is noteworthy that the introduction of Pt-dG did not change the cleavage pattern.
The presence of an n-1 product (10 nt) and the lack of an n-2 product (9 nt) at early time points from C:dG and C:Pt-dG scaffolds indicate the existence of a Pol II pre-translocation state and the absence of a backtracked state. In contrast, the presence of an n-2 product (9 nt) and a lack of an n-1 product (10 nt) at early time points from A:dG, A:Pt-dG, U:dG, and U:Pt-dG scaffolds suggests the existence of backtracked Pol II and a lack of pretranslocation state (Figure 7) . We also performed a pyrophosphate-mediated cleavage assay, which is the reverse reaction of nucleotide addition. This assay cleaves a single 3'end RNA nucleotide when Pol II is at the pre-translocation state. As shown in Table 5 and 
Discussion
Effects on Transcriptional Fidelity and Translesion Bypass. Some DNA lesions significantly increase nucleotide misincorporation in RNA transcripts during Pol II transcriptional bypass (error-prone bypass), whereas others have virtually no effect on Pol II fidelity (error-free bypass). 9, 35 We systematically investigated the effects of the sterically encumbering, monofunctional platinum-DNA adduct on each of the three checkpoint steps of Pol II transcriptional fidelity and elongation.
The influence of the phenanthriplatin-dG adduct on the template strand is significantly different in each of these three steps. The presence of the monofunctional platinum complex does not prevent efficient CTP incorporation at the first checkpoint, which is strikingly distinct from that of cisplatin and other bifunctional platinum compounds. 2 This result is most likely characteristic of all bulky monofunctional platinum-DNA adducts, for we observed a similar result for a pyriplatin-dG lesion on DNA. 14 In the third checkpoint step, the presence of the Pt-DNA lesion causes less than a twofold reduction in transcriptional fidelity. Taken together, data obtained from these three checkpoint steps reveal that a phenanthriplatin Pt-DNA dG adduct reduces total transcription fidelity by ~1200-5000-fold. The presence of the phenanthriplatin DNA adduct leads to rapid, "error-free" addition of the first nucleotide opposite the DNA damage site and a slow, "error-prone" addition for subsequent nucleotide extension downstream of the DNA damage site.
24!
Pol II Processing at a Monofunctional Pt-DNA Adduct is Distinct from that at a Bifunctional Cross-link. It is well documented that certain families of DNA polymerases often incorporate dAMP opposite a damaged DNA base in a non-template manner, a phenomenon that is called the "A-rule." [36] [37] [38] [39] [40] [41] [42] [43] Although the A-rule holds for certain families of DNA polymerases, it is not a universal feature that applies to all polymerases. [44] [45] [46] It was recently reported that Pol II preferentially inserts AMP opposite cisplatin and cyclobutane pyrimidine dimer (CPD) 1,2-intrastrand cross-link lesions. 34 An intriguing question raised by this result is whether the A-rule will apply to other types of lesions. 
Conclusion
In summary, we present a systematic mechanistic analysis of the functional interplay between a site-specific phenanthriplatin-DNA monofunctional dG adduct and the Pol II transcription machinery. Whereas a majority of Pol II elongation complexes stall after rapid, error-free addition of CTP opposite the phenanthriplatin-dG adduct, a small portion of Pol II undergoes slow, error-prone bypass of the phenanthriplatin-dG lesion. These results reveal that Pol II processing of the phenanthriplatin lesion is significantly different from that of the canonical cisplatin DNA 1,2-d(GpG) intrastrand cross-link. Furthermore, the influence of the phenanthriplatin-dG adduct on the template strand is significantly different in each of three transcriptional fidelity checkpoint steps. Our studies provide new insights into how the Pol II transcription machinery processes monofunctional phenanthriplatin-DNA adducts. This knowledge establishes a key structure-function relationship that may underlie the strong differentiation in biological consequences between phenanthriplatin and the classical platinum anticancer drugs now widely used in the clinic.
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Details of purification of DNA template containing a site-specific phenanthriplatin-DNA adduct; MALDI-TOF mass spectrometric data for characterization of DNAs. This material is available free of charge via the Internet at http://pubs.acs.org.
